Cannabis for paediatric epilepsy: challenges and conundrums

Kerrie-Anne Chen, Michelle A Farrar, Michael Cardamone and John A Lawson
Med J Aust 2018; 208 (3): 132-136. || doi: 10.5694/mja17.00699
Published online: 19 February 2018



  • Research is expanding for the use of cannabidiol as an anticonvulsant drug. The mechanism of cannabidiol in paediatric epilepsy is unclear but is thought to play a role in modulation of synaptic transmission.
  • Evidence for its efficacy in treating epilepsy is limited but growing, with a single pharmaceutical company-funded randomised double-blind controlled trial in children with Dravet syndrome.
  • Progress towards the use of medicinal cannabinoids incorporates a complex interplay of social influences and political and legal reform.
  • Access to unregistered but available cannabidiol in Australia outside of clinical trials and compassionate access schemes is state dependent and will require Therapeutic Goods Administration approval, although the cost may be prohibitive.
  • Further clinical trials are needed to clearly define efficacy and safety, particularly long term.


  • Kerrie-Anne Chen1
  • Michelle A Farrar1,2
  • Michael Cardamone1,2
  • John A Lawson1,2

  • 1 Sydney Children's Hospital, Randwick, Sydney, NSW
  • 2 UNSW Sydney, Sydney, NSW

Competing interests:

John Lawson is the lead investigator in the NSW Ministry of Health-funded medical cannabis trials.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

You do not have permission to add a response to this article.